LFVN Q1 FY2026 Summary (Period Ending 9/30/2025)
LifeVantage reported modest revenue growth against the prior year, with Net Income rising significantly to $2.16M (EPS $0.17), largely driven by a sharp decrease in Income Tax Expense ($0.086M vs. $0.752M in 2024). Revenue stabilized at $47.56M, though product concentration risk remains high, with three core brands accounting for 86% of sales. Key operational shifts include a significant revenue surge for the TrueScience line (up over 130%) offsetting a decline in the legacy Protandim line. The company closed operations in the Philippi
...